Skip to main content

Transgenomic's Q1 Sales Sag 20 Percent as R&D Grows and Loss Widens

NEW YORK (GenomeWeb News) — Transgenomic yesterday said first-quarter revenues decreased 20 percent as R&D spending rose 75 percent and its net loss ballooned by 276 percent.
Total receipts for the three months ended March 31 fell to $5.2 million from $6.5 million year over year.
However, CEO Craig Tuttle said revenue from Transgenomic’s reference labs grew 277 percent to $290,000. He said the company saw “continuous quarter over quarter growth in our reference laboratory business and improvement in our pharma contract pipeline.”
R&D spending rose to $1.1 million from $604,000 million year over year.
Transgenomic said its net loss rose to $1.2 million from $318,000 in the year-ago period.
Tuttle said he expects “cost-savings measures” to have an increasing impact over the second half of 2007.
Transgenomic said it had around $7.9 million in cash and cash equivalents as of March 31.

The Scan

WHO OKs Emergency Use of Sinopharm Vaccine

The World Health Organization has granted emergency approval for Sinopharm's SARS-CoV-2 vaccine, the Guardian reports.

Scientific Integrity Panel to Meet

According to the Associated Press, a new US scientific integrity panel is to meet later this week.

Trying in the Eye

NPR reports that a study of Editas Medicine's CRISPR therapy for Leber congenital amaurosis has begun.

PLOS Papers on Cerebellum Epigenetics, Copy Number Signature Tool, Acute Lung Injury Networks

In PLOS this week: epigenetics analysis of brain tissue, bioinformatics tool to find copy number signatures in cancer, and more.